A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Launched by NOVO NORDISK A/S · Jul 7, 2025

Keywords

ClinConnect Summary

This study is looking at how the medication Wegovy® (semaglutide) is used in everyday medical care to help people with obesity. Over about two years, researchers will observe how Wegovy affects participants’ weight, body measurements like waist size, and overall quality of life. The goal is to understand how this treatment works in real-life settings when prescribed by a doctor, rather than in a tightly controlled clinical trial.

People who are 18 years or older and starting Wegovy treatment for the first time may be eligible to join, as long as they meet certain health and treatment criteria and can complete online questionnaires. Participants will receive Wegovy as their doctor recommends, and the study will simply observe their progress without changing their care. It’s important that participants can use an electronic device to report their experiences and that they don’t have certain medical conditions or recent treatments that would exclude them. This study is not yet recruiting, but it aims to provide helpful information about how Wegovy works for people managing obesity in everyday life.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol).
• • Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
• • Male or female, age above or equal to 18 years at time of signing informed consent.
• • Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline.
• • Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access.
• • Fulfil the respective reimbursement criteria in the visit prior to / at baseline in Switzerland and United Kingdom (UK).
• Exclusion criteria:
• • Previous participation in this study. Participation is defined as having given informed consent in this study.
• • Presence of a documented refusal or unwillingness to participate in research.
• • Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK.
• • Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agonist up to 30 days prior to baseline in Spain.
• • Pregnant or women of childbearing potential and not using a highly effective contraceptive method.
• • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation with the study requirements.
• • Individuals who have reported plans to move out in the next 12 months to an area not serviced by their current site.
• • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) in Spain and UK.
• • Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
• • Have had Saxenda reimbursed by basic mandatory health insurance for a cumulative period of more than 12 months prior to baseline in Switzerland.
• • Documented history of diabetes mellitus type 1 and type 2 in Spain.
• • Presence of diabetic complications and/or at risk of hypoglycaemia (with a documented history of frequent hypoglycaemia) in Spain.